<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445728</url>
  </required_header>
  <id_info>
    <org_study_id>CHANGE 001</org_study_id>
    <nct_id>NCT03445728</nct_id>
  </id_info>
  <brief_title>China-Administration of Nicorandil Group（CHANGE）</brief_title>
  <official_title>Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We compared the infarct and edema size in ST-segment elevation acute myocardial infarction&#xD;
      (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) treated by&#xD;
      nicorandil before and after the reperfusion with those standard therapy treated by PCI&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">February 24, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infarct size as measured by cardiac MRI</measure>
    <time_frame>7 days after primary PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size as measured by cardiac MRI</measure>
    <time_frame>6 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correccted TIMI Frame count (cTFC) by CAG</measure>
    <time_frame>before PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correccted TIMI Frame count (cTFC) by CAG</measure>
    <time_frame>After PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG showed ST-T change</measure>
    <time_frame>before primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG showed ST-T change</measure>
    <time_frame>1h-1.5h after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine kinase (CK) level</measure>
    <time_frame>before primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine kinase (CK) level</measure>
    <time_frame>6、12、18、24h after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum myocardial band isoenzyme (MB) level</measure>
    <time_frame>before primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum myocardial band isoenzyme (MB) level</measure>
    <time_frame>6、12、18、24h after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cTn T/I level</measure>
    <time_frame>before primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cTn T/I level</measure>
    <time_frame>6、12、18、24h after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edema size (LV area %) measured by cardiac MRI</measure>
    <time_frame>7 days after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edema size (LV area %) measured by cardiac MRI</measure>
    <time_frame>6 months after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis of microcoronary atrial vessel measured by cardiac MRI</measure>
    <time_frame>7 days after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis of microcoronary atrial vessel measured by cardiac MRI</measure>
    <time_frame>6 months after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Ejection fraction (%) as measured by cardiac MRI</measure>
    <time_frame>7 days after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV Ejection fraction (%) as measured by cardiac MRI</measure>
    <time_frame>6 months after primary PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Death, Spontaneous MI, Stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <condition>Nicorandil</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were randomly assigned to two groups before emergent coronary angiography: those who received intravenous (iv.) nicorandil before and after (ivgtt.) reperfusion with PCI (nicorandil group);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients were randomly assigned to two groups before emergent coronary angiography, those who received placebo before and after reperfusion with PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorandil</intervention_name>
    <description>After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute ST-T elevation MI patients (&lt;12h)&#xD;
&#xD;
          2. undergoing emergency PCI；&#xD;
&#xD;
          3. Subject has read and signed a written, informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SBP&lt;80mmHg；&#xD;
&#xD;
          2. LM stenosis&#xD;
&#xD;
          3. Aortic dissection；&#xD;
&#xD;
          4. MI (&lt;6 month)&#xD;
&#xD;
          5. PCI或CABG (&lt;6 month)&#xD;
&#xD;
          6. Already under the treatment of Nicorandil；&#xD;
&#xD;
          7. Contraindicated or intolerable to Nicorandil&#xD;
&#xD;
          8. severe adverse effects to CMR or MRI；&#xD;
&#xD;
          9. Currently (or within one month) participating in another new drug trial.；&#xD;
&#xD;
         10. Pregnant or lactation period；&#xD;
&#xD;
         11. Severe somatic disease preventing the participant from completing the trial, or based&#xD;
             on the discretion of the investigators, the patient is incapable of participating;&#xD;
             Individuals with abnormal laboratory test results and/or clinical manifestations&#xD;
             rendering them unsuitable to participate as judged by the investigators;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHINA</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Yun Dai Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

